Eric J. Gars
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eric J. Gars has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Amy C. Fan
University of California San Francisco 4 Department of Pathology San Francisco, CA
88 shared publications - Kevin A. Nuno
Cancer Biology Graduate Program, Stanford University School of Medicine
88 shared publications - Paul Phan
Johns Hopkins University School of Medicine, Baltimore, USA
88 shared publications - Ravindra Majeti
Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, USA
88 shared publications - Thomas Köhnke
Stanford University 1 Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine Stanford, California
88 shared publications - Aaron C. Trotman-Grant
Immunology Graduate Program, Stanford University School of Medicine, Stanford, California
81 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction drives oligoclonal T cell expansion
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction drives oligoclonal T cell expansion
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction results in no observable off-target toxicity
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction results in no observable off-target toxicity
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Summary of clinical features of primary B-ALL specimens
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Summary of clinical features of primary B-ALL specimens
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction results in expansion of activated and memory T cells, and decreased frequency of Tregs
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo TR-APC induction results in expansion of activated and memory T cells, and decreased frequency of Tregs
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S9 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Primary B-ALL TR-APCs can be generated via exogenous cytokine stimulation
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S9 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Primary B-ALL TR-APCs can be generated via exogenous cytokine stimulation
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S10 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Primary B-ALL-derived TR-APCs activate T cells in an MHC-restricted manner according to the inflammatory milieu
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S10 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Primary B-ALL-derived TR-APCs activate T cells in an MHC-restricted manner according to the inflammatory milieu
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo doxycycline administration results in significant TR-APC induction throughout tumors
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vivo doxycycline administration results in significant TR-APC induction throughout tumors
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
TR-APC induction results in inflammatory rewiring of the tumor microenvironment.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
TR-APC induction results in inflammatory rewiring of the tumor microenvironment.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vitro re-exposure of T cells from surviving mice demonstrates TR-APC-mediated generation of tumor-specific memory.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
In vitro re-exposure of T cells from surviving mice demonstrates TR-APC-mediated generation of tumor-specific memory.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
TR-APC induction in solid tumor models attenuates tumor growth kinetics and prolongs survival
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
TR-APC induction in solid tumor models attenuates tumor growth kinetics and prolongs survival